Results 171 to 180 of about 349,498 (354)

Prognostic impact of iron deficiency in new‐onset chronic heart failure: Danish Heart Failure Registry insights

ESC Heart Failure, Volume 12, Issue 2, Page 1346-1357, April 2025.
Abstract Aims Iron deficiency (ID) is prevalent in chronic heart failure (HF) but lacks a consensus definition. This study evaluates the prevalence and the prognostic impact of ID using different criteria on all‐cause and cardiovascular mortality, as well as first hospitalization for HF in patients with new‐onset chronic HF.
Abdullahi Ahmed Mohamed, Daniel Mølager Christensen, Milan Mohammad, Christian Torp‐Pedersen, Lars Køber, Emil Loldrup Fosbøl, Tor Biering‐Sørensen, Morten Lock Hansen, Mariam Elmegaard Malik, Nina Nouhravesh, Charlotte Anderrson, Morten Schou, Gunnar Gislason   +12 more
wiley   +1 more source

Development, validation, and application of a fast, simple, and robust SPE-based LC-MS/MS method for quantification of angiotensin I-converting enzyme inhibiting tripeptides Val-Pro-Pro, Ile-Pro-Pro, and Leu-Pro-Pro in yoghurt and other fermented dairy products

, 2019
Simon Moosmang, Aino Siltari, Marie-Theres Bolzer, Stefan Kiechl, Sonja Sturm, Hermann Stuppner   +5 more
openalex   +2 more sources

Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin II Receptor Blockers

, 2020
Ankur Kalra, Edward S. Hawkins, Amy S. Nowacki, Vardhmaan Jain, Alex Milinovich, Joshua Saef, George Thomas, Surafel Gebreselassie, Sadashiva S. Karnik, Lara Jehi, James B. Young, Lars G. Svensson, Mina K. Chung, Neil Mehta   +13 more
openalex   +2 more sources

FDG PET/CT imaging and circulating biomarkers of inflammation in desmoplakin cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1485-1489, April 2025.
Abstract Aims Inflammation has been implicated in the pathogenesis of desmoplakin (DSP) cardiomyopathy, and retrospective studies have described abnormal myocardial fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) findings in symptomatic patients eventually diagnosed with DSP cardiomyopathy.
Sanjay Divakaran, Vinay Randhawa, Usman A. Tahir, Matthew Robertson, Anam A. Waheed, Anna Perillo, Leanne Barrett, Ron Blankstein, Mark W. Feinberg, Marcelo F. Di Carli, Neal K. Lakdawala   +10 more
wiley   +1 more source

Chemical Composition, Amino Acid Profile and Angiotensin Converting Enzyme (ACE) Inhibitory Activities of Skipjack (Katsuwonus pelamis) Roe Hydrolyzate

, 2020
Max Robinson Wenno, Johanna Louretha Thenu, Martha L. Wattimena   +2 more
openalex   +1 more source

Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. [PDF]

, 1990
Andrea Remuzzi, Stefania Puntorieri, Cristina Battaglia, Tullio Bertani, Giuseppe Remuzzi   +4 more
openalex   +1 more source

Mortality risk stratification for Takotsubo syndrome: Evaluating CRP measurement alongside the InterTAK prognostic score

ESC Heart Failure, Volume 12, Issue 2, Page 1427-1436, April 2025.
Abstract Background and objectives Initially described as a benign acute cardiomyopathy, Takotsubo syndrome has been linked to elevated mortality rates. Emerging evidence suggests that unresolved myocardial inflammation may contribute to this adverse prognosis.
Loïc Faucher, Kensuke Matsushita, Shinnosuke Kikuchi, Taraneh Tatarcheh, Benjamin Marchandot, Amandine Granier, Said Amissi, Antonin Trimaille, Laurence Jesel, Patrick Ohlmann, Kiyoshi Hibi, Valérie Schini‐Kerth, Olivier Morel   +12 more
wiley   +1 more source

Barely There But Existent: Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema. [PDF]

Cureus
Butt MA, Kumar S, Sarwer SM, Manna D.
europepmc   +1 more source

Decrease of Tissue Angiotensin I-Converting Enzyme Activity upon Feeding Sour Milk in Spontaneously Hypertensive Rats [PDF]

, 1996
Yasunori Nakamura, Osamu Masuda, Toshiaki Takano   +2 more
openalex   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source